HRP20240022T1 - Režim za doziranje propuštenih doza injektibilnih estera paliperidona s produljenim djelovanjem - Google Patents
Režim za doziranje propuštenih doza injektibilnih estera paliperidona s produljenim djelovanjem Download PDFInfo
- Publication number
- HRP20240022T1 HRP20240022T1 HRP20240022TT HRP20240022T HRP20240022T1 HR P20240022 T1 HRP20240022 T1 HR P20240022T1 HR P20240022T T HRP20240022T T HR P20240022TT HR P20240022 T HRP20240022 T HR P20240022T HR P20240022 T1 HRP20240022 T1 HR P20240022T1
- Authority
- HR
- Croatia
- Prior art keywords
- paliperidone palmitate
- injectable
- use according
- month
- release
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562144054P | 2015-04-07 | 2015-04-07 | |
| US201562162596P | 2015-05-15 | 2015-05-15 | |
| EP20169861.0A EP3744326B1 (en) | 2015-04-07 | 2016-03-30 | Dosing regimen for missed doses for long-acting injectable paliperidone esters |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20240022T1 true HRP20240022T1 (hr) | 2024-03-29 |
Family
ID=57072843
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20240022TT HRP20240022T1 (hr) | 2015-04-07 | 2016-03-30 | Režim za doziranje propuštenih doza injektibilnih estera paliperidona s produljenim djelovanjem |
| HRP20201027TT HRP20201027T1 (hr) | 2015-04-07 | 2016-03-30 | Režim doziranja za propuštene doze injektibilnih estera paliperidona s produljenim djelovanjem |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201027TT HRP20201027T1 (hr) | 2015-04-07 | 2016-03-30 | Režim doziranja za propuštene doze injektibilnih estera paliperidona s produljenim djelovanjem |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US10143693B2 (enExample) |
| EP (3) | EP4349323A3 (enExample) |
| JP (3) | JP6728221B2 (enExample) |
| KR (3) | KR20250013293A (enExample) |
| AU (4) | AU2016244801B2 (enExample) |
| BR (1) | BR112017021383A2 (enExample) |
| CA (2) | CA3088401A1 (enExample) |
| CY (1) | CY1123203T1 (enExample) |
| DK (2) | DK3744326T3 (enExample) |
| EA (1) | EA037185B1 (enExample) |
| ES (2) | ES2967585T3 (enExample) |
| FI (1) | FI3744326T3 (enExample) |
| HR (2) | HRP20240022T1 (enExample) |
| HU (2) | HUE049485T2 (enExample) |
| IL (3) | IL254669B2 (enExample) |
| LT (2) | LT3744326T (enExample) |
| MA (1) | MA41917B1 (enExample) |
| MD (2) | MD3280416T2 (enExample) |
| NZ (1) | NZ735952A (enExample) |
| PL (2) | PL3744326T3 (enExample) |
| PT (2) | PT3280416T (enExample) |
| RS (2) | RS60510B1 (enExample) |
| SI (2) | SI3280416T1 (enExample) |
| SM (2) | SMT202000351T1 (enExample) |
| TW (1) | TWI694825B (enExample) |
| UA (1) | UA118732C2 (enExample) |
| WO (1) | WO2016164218A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3744326T3 (fi) | 2015-04-07 | 2024-02-02 | Janssen Pharmaceutica Nv | Annosteluohjelma pitkävaikutteisten injektoitavien paliperidoniestereiden ottamatta jääneille annoksille |
| AU2018354431B2 (en) | 2017-10-27 | 2024-01-18 | Geneora Pharma (Shijiazhuang) Co., Ltd. | Dosage regimen of paliperidone palmitate extended-release injectable suspension |
| MX2023006370A (es) * | 2020-11-30 | 2023-08-07 | Janssen Pharmaceutica Nv | Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. |
| SMT202400077T1 (it) * | 2020-11-30 | 2024-03-13 | Janssen Pharmaceutica Nv | Regimi di dosaggio associati con formulazioni iniettabili di paliperidone a rilascio prolungato |
| CA3203015A1 (en) * | 2020-11-30 | 2022-06-02 | Janssen Pharmaceutica Nv | Dosing regimens associated with extended release paliperidone injectable formulations |
| CN116528837B (zh) | 2020-11-30 | 2025-03-14 | 詹森药业有限公司 | 用于确保棕榈酸帕潘立酮制剂再悬浮的方法 |
| MX2024002215A (es) | 2021-08-20 | 2024-05-10 | Janssen Pharmaceutica Nv | Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada. |
| AU2022337993A1 (en) * | 2021-08-30 | 2024-04-11 | Janssen Pharmaceutica Nv | Dosing regimens associated with extended release paliperidone injectable formulations |
| KR102869809B1 (ko) | 2023-11-21 | 2025-10-13 | 주식회사 엘지에너지솔루션 | 양극 및 이를 포함하는 전고체 전지 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5254556A (en) | 1988-11-07 | 1993-10-19 | Janssen Pharmaceutica N.V. | 3-piperidinyl-1,2-benzisoxazoles |
| US5158952A (en) | 1988-11-07 | 1992-10-27 | Janssen Pharmaceutica N.V. | 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use |
| TW487572B (en) | 1996-05-20 | 2002-05-21 | Janssen Pharmaceutica Nv | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
| UA72189C2 (uk) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
| JP5249748B2 (ja) | 2005-04-25 | 2013-07-31 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 無菌３−［２−［４−（６−フルオロ−１，２−ベンズイソオキサゾール−３−イル）−１−ピペリジニル］エチル］−６，７，８，９−テトラヒドロ−９−ヒドロキシ−２−メチル−４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オンパルミチン酸エステルの製造 |
| CN101932327A (zh) * | 2007-12-19 | 2010-12-29 | 詹森药业有限公司 | 与长效注射用帕潘立酮酯相关的给药方案 |
| WO2011042453A1 (en) * | 2009-10-06 | 2011-04-14 | Ascendis Pharma As | Subcutaneous paliperidone composition |
| KR20120116401A (ko) | 2009-10-30 | 2012-10-22 | 얀센 파마슈티카 엔.브이. | 장기-작용성의 주사가능한 팔리페리돈 에스테르와 관련된 투약 요법 |
| EP2529757B1 (en) * | 2011-05-31 | 2014-01-08 | Laboratorios Farmaceuticos Rovi, S.A. | Paliperidone implant formulation |
| FI3744326T3 (fi) | 2015-04-07 | 2024-02-02 | Janssen Pharmaceutica Nv | Annosteluohjelma pitkävaikutteisten injektoitavien paliperidoniestereiden ottamatta jääneille annoksille |
-
2016
- 2016-03-30 FI FIEP20169861.0T patent/FI3744326T3/fi active
- 2016-03-30 SM SM20200351T patent/SMT202000351T1/it unknown
- 2016-03-30 SI SI201630743T patent/SI3280416T1/sl unknown
- 2016-03-30 EA EA201792209A patent/EA037185B1/ru unknown
- 2016-03-30 HR HRP20240022TT patent/HRP20240022T1/hr unknown
- 2016-03-30 IL IL254669A patent/IL254669B2/en unknown
- 2016-03-30 EP EP23214037.6A patent/EP4349323A3/en active Pending
- 2016-03-30 ES ES20169861T patent/ES2967585T3/es active Active
- 2016-03-30 DK DK20169861.0T patent/DK3744326T3/da active
- 2016-03-30 JP JP2017552890A patent/JP6728221B2/ja active Active
- 2016-03-30 NZ NZ735952A patent/NZ735952A/en unknown
- 2016-03-30 WO PCT/US2016/024841 patent/WO2016164218A1/en not_active Ceased
- 2016-03-30 ES ES16777058T patent/ES2802299T3/es active Active
- 2016-03-30 UA UAA201710765A patent/UA118732C2/uk unknown
- 2016-03-30 LT LTEP20169861.0T patent/LT3744326T/lt unknown
- 2016-03-30 HU HUE16777058A patent/HUE049485T2/hu unknown
- 2016-03-30 DK DK16777058.5T patent/DK3280416T3/da active
- 2016-03-30 RS RS20200726A patent/RS60510B1/sr unknown
- 2016-03-30 HU HUE20169861A patent/HUE065435T2/hu unknown
- 2016-03-30 LT LTEP16777058.5T patent/LT3280416T/lt unknown
- 2016-03-30 MD MDE20180155T patent/MD3280416T2/ro unknown
- 2016-03-30 EP EP16777058.5A patent/EP3280416B1/en active Active
- 2016-03-30 BR BR112017021383-4A patent/BR112017021383A2/pt not_active Application Discontinuation
- 2016-03-30 SM SM20230478T patent/SMT202300478T1/it unknown
- 2016-03-30 RS RS20231239A patent/RS65024B1/sr unknown
- 2016-03-30 AU AU2016244801A patent/AU2016244801B2/en active Active
- 2016-03-30 MA MA41917A patent/MA41917B1/fr unknown
- 2016-03-30 KR KR1020257000920A patent/KR20250013293A/ko active Pending
- 2016-03-30 PL PL20169861.0T patent/PL3744326T3/pl unknown
- 2016-03-30 EP EP20169861.0A patent/EP3744326B1/en active Active
- 2016-03-30 PT PT167770585T patent/PT3280416T/pt unknown
- 2016-03-30 PL PL16777058T patent/PL3280416T3/pl unknown
- 2016-03-30 KR KR1020177031672A patent/KR102606678B1/ko active Active
- 2016-03-30 KR KR1020237040260A patent/KR102755145B1/ko active Active
- 2016-03-30 IL IL309340A patent/IL309340B1/en unknown
- 2016-03-30 SI SI201631783T patent/SI3744326T1/sl unknown
- 2016-03-30 HR HRP20201027TT patent/HRP20201027T1/hr unknown
- 2016-03-30 MD MDE20210632T patent/MD3744326T2/ro unknown
- 2016-03-30 PT PT201698610T patent/PT3744326T/pt unknown
- 2016-04-01 CA CA3088401A patent/CA3088401A1/en not_active Abandoned
- 2016-04-01 TW TW105110443A patent/TWI694825B/zh active
- 2016-04-01 CA CA2925908A patent/CA2925908C/en active Active
- 2016-04-05 US US15/090,889 patent/US10143693B2/en active Active
-
2019
- 2019-12-23 JP JP2019231631A patent/JP7228503B2/ja active Active
-
2020
- 2020-07-06 CY CY20201100618T patent/CY1123203T1/el unknown
- 2020-09-21 AU AU2020239611A patent/AU2020239611B2/en active Active
-
2021
- 2021-05-24 JP JP2021086909A patent/JP7422277B2/ja active Active
-
2022
- 2022-08-23 AU AU2022221405A patent/AU2022221405B2/en active Active
-
2024
- 2024-10-31 AU AU2024227790A patent/AU2024227790A1/en active Pending
-
2025
- 2025-10-19 IL IL324059A patent/IL324059A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201027T1 (hr) | Režim doziranja za propuštene doze injektibilnih estera paliperidona s produljenim djelovanjem | |
| FI3515937T3 (fi) | Refraktaarisen migreenin hoito | |
| PE20190205A1 (es) | Uso de inhibidores de miostatina y terapias de combinacion | |
| MX2021009942A (es) | Composiciones que comprenden 5-metoxi-n, n-dimetiltriptamina (5-meo-dmt) para su uso en el tratamiento de trastornos mentales. | |
| MX385287B (es) | Anticuerpos anti-puntos de control inmunitarios para usarse en el tratamiento de la enfermedad de alzheimer. | |
| MX388735B (es) | Combinaciones de amisulprida y otro antiemetico para tratar nausea y vomito. | |
| BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
| JP2013509435A5 (enExample) | ||
| NZ599558A (en) | Dosing regimen associated with long-acting injectable paliperidone esters | |
| MX385543B (es) | Uso de un anticuerpo biespecífico para tratar cáncer de linfocitos b. | |
| MX2021001083A (es) | Regimen posologico para anticuerpos biespecificos contra bcma-cd3. | |
| BR112018068512A2 (pt) | métodos para tratar câncer de mama er+, her2-, hrg+ com o uso de terapias de combinação que compreendem um anticorpo anti-erbb3 | |
| HRP20180301T1 (hr) | Postupci liječenja psorijaze uporabom il-17 antagonista | |
| MX2023012465A (es) | Regimen de dosificacion de anti-ifnar1 para inyeccion subcutanea. | |
| EA201992612A1 (ru) | Схемы применения антагониста гонадотропин-высвобождающего гормона для лечения эндометриоза | |
| JP2016512564A5 (enExample) | ||
| BR112017014793A2 (pt) | regime de dosagem para antagonistas de madcam | |
| HRP20230894T1 (hr) | Režimi i postupci liječenja multiple skleroze ofatumumabom | |
| JP2018510894A5 (enExample) | ||
| BR112022025658A2 (pt) | Método para controlar uma taxa de liberação de um agente terapêutico, dispositivo implantável para liberação de um agente terapêutico, e, formulação de um agente terapêutico | |
| ZA202400851B (en) | Dosing regimens associated with extended release paliperidone injectable formulations | |
| BR112019002461A2 (pt) | regime de dosagem para tratamento de tumores sólidos | |
| MX2023006366A (es) | Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. | |
| MX2021013910A (es) | Metodos para administrar un anticuerpo anti-cd38 para tratar el mieloma multiple. | |
| MX2022005628A (es) | Regimen de dosificacion para agentes anti-bcma. |